adplus-dvertising
Connect with us

Business

Biden to receive COVID-19 vaccine as Trump remains on sidelines – The Globe and Mail

Published

 on


U.S. president-elect Joe Biden, with vice-president-elect Kamala Harris, speaks about the COVID-19 crisis before introducing nominees to his incoming administration in Wilmington, Del., on Dec. 11, 2020. Biden is set to receive the COVID-19 vaccine on Monday.

JIM WATSON/AFP/Getty Images

The leader of the Trump administration’s vaccination program says people who have been infected with the coronavirus – a group that includes President Donald Trump – should receive the vaccine.

Moncef Slaoui, the chief adviser of Operation Warp Speed, told CNN’s State of the Union on Sunday that the vaccine is safe for those who have recovered and offers stronger and potentially longer protection than does the virus itself.

“We know that infection doesn’t induce a very strong immune response and it wanes over time. So I think, as a clear precaution, it is appropriate to be vaccinated because it’s safe,” he said. “I think people should be vaccinated, indeed.”

Story continues below advertisement

Trump is now one of the only senior-most U.S. officials who has not received the first of two vaccination shots, which began being administered last week as part of the largest vaccination campaign in the country’s history. Vice-President Mike Pence, House Speaker Nancy Pelosi, D-Calif., and Senate Majority Leader Mitch McConnell, R-Ky., all were given doses Friday. President-elect Joe Biden was to receive his Monday.

All have chosen to publicize their injections as part of a campaign to convince a skeptical public that the vaccines are safe and effective, in hopes of finally putting an end to a pandemic that has killed more than 317,000 people in the United States and upended life around the globe.

Trump, who in the past has spread misinformation about vaccine risks, tweeted earlier this month that he was “not scheduled” to take the vaccine, but looked “forward to doing so at the appropriate time.” The White House says he is still discussing timing with his doctors.

Trump was hospitalized with COVID-19 in October and given an experimental monoclonal antibody treatment that he credited for his swift recovery.

A Centers for Disease Control and Prevention advisory board has said people who received that treatment should wait at least 90 days to be vaccinated to avoid any potential interference.

“When the time is right, I’m sure he will remain willing to take it,” White House spokesperson Brian Morgenstern echoed Friday. “It’s just something we’re working through.”

Whose COVID-19 vaccines are coming to Canada, and when? How well do they work? Everything you need to know

Trump has spent the last week largely out of sight as he continues to stew about his election loss and floats increasingly outlandish schemes to remain in power. It’s an approach that has bewildered top aides who see his silence as a missed opportunity for the president, who leaves office Jan. 20, to claim credit for helping oversee the speedy development of the vaccine and to burnish his legacy.

Story continues below advertisement

Trump has also come under criticism for failing to take the vaccine himself as an example to help allay concerns about its safety, especially among Republicans.

The CDC’s Advisory Committee on Immunization Practices said the Pfizer-BioNTech vaccine, which was the first to receive authorization, “is safe and likely efficacious” in people who have been infected with COVID-19 and “should be offered regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.”

While there is no recommended minimum wait time between infection and vaccination, because reinfection is uncommon in the three months after a person is infected, the committee said people who tested positive in the preceding 90 days “may delay vaccination until near the end of this period, if desired.”

But the advisers also recommended that those who received the kind of treatment Trump did should put off being vaccinated for at least 90 days.

“Currently, there are no data on the safety and efficacy of Pfizer-BioNTech COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment,” they wrote, recommending that vaccination “be deferred for at least 90 days, as a precautionary measure until additional information becomes available, to avoid interference of the antibody treatment with vaccine-induced immune responses.”

Surgeon General Jerome Adams cited that recommendation on CBS’s Face the Nation on Sunday when asked if Trump planned to receive the shot on camera.

Story continues below advertisement

“From a scientific point of view, I will remind people that the president has had COVID within the last 90 days. He received the monoclonal antibodies. And that is actually one scenario where we tell people maybe you should hold off on getting the vaccine, talk to your health provider to find out the right time,” Adams said.

White House press secretary Kayleigh McEnany has given other explanations for the delay. She told reporters last week that Trump was holding off, in part, “to show Americans that our priority are the most vulnerable.”

“The President wants to send a parallel message, which is, you know, our long-term care facility residents and our frontline workers are paramount in importance, and he wants to set an example in that regard,” she said.

Dr. Anthony Fauci, the nation’s top infectious diseases expert, is among those who have recommended that Trump be vaccinated without delay.

“Even though the president himself was infected, and he has, likely, antibodies that likely would be protective, we’re not sure how long that protection lasts. So, to be doubly sure, I would recommend that he get vaccinated,” he told ABC News.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending